Analytical Data
-
Gene name
E1A91
- Application
-
Alternative Names
E1A91；
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A5D2ZVD2
-
Expression Region
1-562aa
-
AA Sequence
MSTGMSKLGDKPEAAPNDAADYEDEEEDLSWSSDSEIVEALDYLDSKVDDEFIDSSFTLASRRPNAHGGVHSRPNSSALQPLSNRNQKFSNHIRASPLEEWEGRINVGMSNSVTTAIRESVREMAIGKTKTTEKADRATVEQAIDPRTRMVLFKMLNRGVFHDINGCISTGKEANVYHATKSDGQELAIKVYKTSVLVFKDRDRYVQGDYRFRYGYCKHNPRKMVKTWAEKEMRNLMRLKAAGIRCPTPLLLRLHVLVMEFIGKAGWAAPRLKVAALSLDKLRECYVEMIVAMQTLYQKCKLVHGDLSEYNILFYEGHLYIIDVSQAVDLDHPHALDFLREDCIHVSDFFKKHGVAVMTIRELFDFIVDPTITDGSVDSYLEKVQQKILARGDMSVEDEIADSVFVQTYIPKTLDHVKNVEEDVIRITSGKDTGDLYYKTITGLKEALPKDQSSPMEKQQGDTNTRSVEGSMGNPSGHSNSQESESESESPSGSETDGDEENLSGSEGKGPLSDSSAQVDKKAARKENKKKVKEEKREARKTKVPKAVKKRKKKLAKAHKTR
-
Molecular Weight
63.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
E1A91 recombinant protein is derived from the adenoviral early region 1A (E1A) gene, which plays a crucial role in the viral life cycle and the regulation of host cellular processes. Research on E1A91 has gained significant interest due to its potential applications in gene therapy, cancer treatment, and molecular biology. E1A proteins are known to interact with various cellular proteins, facilitating modulation of gene expression and cell cycle regulation, thereby influencing processes such as apoptosis and differentiation. The 91 amino acid isoform of E1A, specifically, has been shown to have unique properties that enhance its ability to disrupt normal cellular signaling pathways, making it a key focus in studies aimed at understanding tumorigenesis and oncogenic mechanisms. Investigations into E1A91 recombinant protein not only contribute to the basic understanding of viral-host interactions but also offer insights into developing novel therapeutic strategies, including the use of E1A91 in oncolytic virotherapy. Furthermore, elucidating the structure-function relationship of E1A91 is critical for designing effective adenoviral vectors for targeted gene delivery. As a result, the study of E1A91 recombinant protein is positioned at the intersection of virology, cancer research, and biotechnology, highlighting its importance in both biomedicine and therapeutic innovation.
